Breath THC Detection Windows Depend on Actual Collection Times

A scheduled half-hour breath sample may not actually be collected at half an hour. In a controlled cannabis-smoking study, early breath collections were delayed because other specimens were collected first. Reading nominal times as exact times would misstate the evidence.

The collection sequence changed the timeline

Himes and colleagues studied breath cannabinoids in 13 chronic and 11 occasional cannabis smokers. Oral-fluid sampling preceded breath sampling, and cannabis-related dry mouth prolonged some oral-fluid collections.

The first post-smoking breath collection occurred at a mean of 0.89 hours in chronic smokers and 0.95 hours in occasional smokers. The paper therefore reported actual collection times alongside the intended schedule. These values describe this protocol, not a standard delay inherent to every breath device.

Detection was incomplete even soon after smoking

At those first actual collection times, all chronic smokers and 90.9% of occasional smokers had detectable breath THC. One occasional smoker never produced a positive breath sample. Later positivity declined, although an isolated chronic-user sample was positive at 4.2 hours after a negative earlier specimen.

No breath sample contained detectable THCCOOH, and only one contained CBN. Those findings concern analytes recovered by this collection and analytical system. They should not be treated as a universal description of all breath matrices and instruments.

Detection time is not a driving-clearance time

The study’s sensitivity, actual collection times and limited sampling schedule all affect its observed detection window. A negative result cannot establish that no cannabis was used, while a positive result does not itself quantify a person’s driving impairment.

The publication also prompted a scientific comment and an author reply about interpretation. Neither should be confused with an independent replication. The original paper itself acknowledged missed detection soon after smoking and the need to validate predictive value.

In a case review, request collection start and end times and the order of any other testing, rather than relying on a rounded label such as “30 minutes.” Keep that timeline separate from the functional question discussed in interpreting THC levels and impairment.

Primary research

Sarah K. Himes and colleagues. Clinical chemistry (2013). Cannabinoids in Exhaled Breath following Controlled Administration of Smoked Cannabis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us